{"id":21098,"date":"2025-01-09T22:02:27","date_gmt":"2025-01-09T14:02:27","guid":{"rendered":"https:\/\/flcube.com\/?p=21098"},"modified":"2025-01-09T22:02:30","modified_gmt":"2025-01-09T14:02:30","slug":"alloy-therapeutics-and-sanofi-collaborate-on-cns-drug-development-with-anticlastic-antisense-platform","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=21098","title":{"rendered":"Alloy Therapeutics and Sanofi Collaborate on CNS Drug Development with AntiClastic Antisense Platform"},"content":{"rendered":"\n

US-based Alloy Therapeutics Inc. has announced a target-specific collaboration and license agreement with Sanofi (NASDAQ: SNY<\/a>), the French pharmaceutical giant. The partnership aims to leverage Alloy\u2019s neuroscience expertise to develop a novel drug targeting the central nervous system (CNS) based on Alloy\u2019s proprietary AntiClastic Antisense Platform. This technology, launched by Alloy in 2023, enables the development of antisense therapies with intracellular RNA targets.<\/p>\n\n\n\n

Financial Terms of the Agreement<\/strong>
Under the terms of the agreement, Sanofi will pay Alloy an aggregate of USD 27.5 million in upfront license fees and near-term preclinical milestone payments. Additionally, Alloy will be eligible to receive discovery, development, and commercial milestone payments exceeding USD 400 million, along with tiered royalties on product sales.<\/p>\n\n\n\n

Significance of the Collaboration<\/strong>
This collaboration highlights the potential of Alloy Therapeutics’ AntiClastic Antisense Platform in developing innovative treatments for central nervous system disorders. By partnering with Sanofi, a global leader in pharmaceuticals, Alloy aims to accelerate the development and commercialization of novel CNS therapies, potentially improving patient outcomes and addressing significant unmet medical needs.-Fineline Info & Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

US-based Alloy Therapeutics Inc. has announced a target-specific collaboration and license agreement with Sanofi (NASDAQ:…<\/p>\n","protected":false},"author":1,"featured_media":21100,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[2233,867,64,147],"class_list":["post-21098","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-alloy-therapeutics","tag-nasdaq-sny","tag-rnai-aso","tag-sanofi"],"yoast_head":"\nAlloy Therapeutics and Sanofi Collaborate on CNS Drug Development with AntiClastic Antisense Platform - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"US-based Alloy Therapeutics Inc. has announced a target-specific collaboration and license agreement with Sanofi (NASDAQ: SNY), the French pharmaceutical giant. The partnership aims to leverage Alloy\u2019s neuroscience expertise to develop a novel drug targeting the central nervous system (CNS) based on Alloy\u2019s proprietary AntiClastic Antisense Platform. This technology, launched by Alloy in 2023, enables the development of antisense therapies with intracellular RNA targets.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=21098\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Alloy Therapeutics and Sanofi Collaborate on CNS Drug Development with AntiClastic Antisense Platform\" \/>\n<meta property=\"og:description\" content=\"US-based Alloy Therapeutics Inc. has announced a target-specific collaboration and license agreement with Sanofi (NASDAQ: SNY), the French pharmaceutical giant. The partnership aims to leverage Alloy\u2019s neuroscience expertise to develop a novel drug targeting the central nervous system (CNS) based on Alloy\u2019s proprietary AntiClastic Antisense Platform. This technology, launched by Alloy in 2023, enables the development of antisense therapies with intracellular RNA targets.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=21098\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-01-09T14:02:27+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-01-09T14:02:30+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/01\/0914.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=21098#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=21098\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Alloy Therapeutics and Sanofi Collaborate on CNS Drug Development with AntiClastic Antisense Platform\",\"datePublished\":\"2025-01-09T14:02:27+00:00\",\"dateModified\":\"2025-01-09T14:02:30+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=21098\"},\"wordCount\":188,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=21098#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/01\\\/0914.png\",\"keywords\":[\"Alloy Therapeutics\",\"NASDAQ: SNY\",\"RNAi \\\/ ASO\",\"Sanofi\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=21098#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=21098\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=21098\",\"name\":\"Alloy Therapeutics and Sanofi Collaborate on CNS Drug Development with AntiClastic Antisense Platform - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=21098#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=21098#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/01\\\/0914.png\",\"datePublished\":\"2025-01-09T14:02:27+00:00\",\"dateModified\":\"2025-01-09T14:02:30+00:00\",\"description\":\"US-based Alloy Therapeutics Inc. has announced a target-specific collaboration and license agreement with Sanofi (NASDAQ: SNY), the French pharmaceutical giant. The partnership aims to leverage Alloy\u2019s neuroscience expertise to develop a novel drug targeting the central nervous system (CNS) based on Alloy\u2019s proprietary AntiClastic Antisense Platform. This technology, launched by Alloy in 2023, enables the development of antisense therapies with intracellular RNA targets.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=21098#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=21098\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=21098#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/01\\\/0914.png\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/01\\\/0914.png\",\"width\":1080,\"height\":608,\"caption\":\"Alloy Therapeutics and Sanofi Collaborate on CNS Drug Development with AntiClastic Antisense Platform\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=21098#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Alloy Therapeutics and Sanofi Collaborate on CNS Drug Development with AntiClastic Antisense Platform\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Alloy Therapeutics and Sanofi Collaborate on CNS Drug Development with AntiClastic Antisense Platform - Insight, China's Pharmaceutical Industry","description":"US-based Alloy Therapeutics Inc. has announced a target-specific collaboration and license agreement with Sanofi (NASDAQ: SNY), the French pharmaceutical giant. The partnership aims to leverage Alloy\u2019s neuroscience expertise to develop a novel drug targeting the central nervous system (CNS) based on Alloy\u2019s proprietary AntiClastic Antisense Platform. This technology, launched by Alloy in 2023, enables the development of antisense therapies with intracellular RNA targets.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=21098","og_locale":"en_US","og_type":"article","og_title":"Alloy Therapeutics and Sanofi Collaborate on CNS Drug Development with AntiClastic Antisense Platform","og_description":"US-based Alloy Therapeutics Inc. has announced a target-specific collaboration and license agreement with Sanofi (NASDAQ: SNY), the French pharmaceutical giant. The partnership aims to leverage Alloy\u2019s neuroscience expertise to develop a novel drug targeting the central nervous system (CNS) based on Alloy\u2019s proprietary AntiClastic Antisense Platform. This technology, launched by Alloy in 2023, enables the development of antisense therapies with intracellular RNA targets.","og_url":"https:\/\/flcube.com\/?p=21098","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-01-09T14:02:27+00:00","article_modified_time":"2025-01-09T14:02:30+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/01\/0914.png","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=21098#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=21098"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Alloy Therapeutics and Sanofi Collaborate on CNS Drug Development with AntiClastic Antisense Platform","datePublished":"2025-01-09T14:02:27+00:00","dateModified":"2025-01-09T14:02:30+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=21098"},"wordCount":188,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=21098#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/01\/0914.png","keywords":["Alloy Therapeutics","NASDAQ: SNY","RNAi \/ ASO","Sanofi"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=21098#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=21098","url":"https:\/\/flcube.com\/?p=21098","name":"Alloy Therapeutics and Sanofi Collaborate on CNS Drug Development with AntiClastic Antisense Platform - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=21098#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=21098#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/01\/0914.png","datePublished":"2025-01-09T14:02:27+00:00","dateModified":"2025-01-09T14:02:30+00:00","description":"US-based Alloy Therapeutics Inc. has announced a target-specific collaboration and license agreement with Sanofi (NASDAQ: SNY), the French pharmaceutical giant. The partnership aims to leverage Alloy\u2019s neuroscience expertise to develop a novel drug targeting the central nervous system (CNS) based on Alloy\u2019s proprietary AntiClastic Antisense Platform. This technology, launched by Alloy in 2023, enables the development of antisense therapies with intracellular RNA targets.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=21098#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=21098"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=21098#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/01\/0914.png","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/01\/0914.png","width":1080,"height":608,"caption":"Alloy Therapeutics and Sanofi Collaborate on CNS Drug Development with AntiClastic Antisense Platform"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=21098#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Alloy Therapeutics and Sanofi Collaborate on CNS Drug Development with AntiClastic Antisense Platform"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/01\/0914.png","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/21098","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=21098"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/21098\/revisions"}],"predecessor-version":[{"id":21101,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/21098\/revisions\/21101"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/21100"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=21098"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=21098"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=21098"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}